Sangamo Therapeutics IncSangamo Therapeutics Inc - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

The webpage includes a Q&A section on Sangamo Therapeutics Inc. Browse to the bottom of this webpage for potential risks for Sangamo Therapeutics Inc based on industry, geography and size. If you work at Sangamo Therapeutics Inc and you wish to use your ESG rating, please contact us.

Sangamo Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.5; made up of an environmental score of 0.0, social score of 0.0 and governance score of 1.6.

SDG Transparency Score for Sangamo Therapeutics Inc 

0.5

Low Impact
0 - 3
Medium
4 - 6
High
7 - 10
Last Score Update: 2024-05-01
What drives the score for Sangamo Therapeutics Inc 
0.0

Environmental

0.0

Social

1.6

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Caladrius Biosciences Inc
8.0
High
1Can Fite Biopharma Ltd
8.0
High
.........
1898Zota Health Care Ltd
0.7
Low
1898cbdMD Inc
0.7
Low
1924Sangamo Therapeutics Inc
0.5
Low
1924Beximco Pharmaceuticals Ltd
0.5
Low
1924Acucela Inc
0.5
Low
1970Zyden Gentec Ltd
0.0
Low
1970iNtRON Biotechnology Inc
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Sangamo Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc report the average age of the workforce?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc disclose cybersecurity risks?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc offer flexible work?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc conduct supply chain audits?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc disclose water use targets?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Sangamo Therapeutics Inc have a product recall in the last two years?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc disclose incidents of discrimination?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Sangamo Therapeutics Inc issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc disclose parental leave metrics?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Sangamo Therapeutics Inc involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc disclose its waste policy?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc report according to TCFD requirements?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc disclose energy use targets?

LockedSign up for free to unlock

Does Sangamo Therapeutics Inc disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Sangamo Therapeutics Inc have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Sangamo Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.

Sorry!

Failed to process!